Sotagliflozin
Zynquista (sotagliflozin) is a small molecule pharmaceutical. Sotagliflozin was first approved as Zynquista on 2019-04-26. It has been approved in Europe to treat type 1 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1.
| Trade Name | Zynquista |
|---|---|
| Common Name | Sotagliflozin |
| Indication | type 1 diabetes mellitus |
| Drug Class | Phlorozin derivatives, phenolic glycosides |
